Atrial fibrillation.

Atrial fibrillation.nounces Initiation of a phase II multi-center study for Biological therapy of postoperative atrial fibrillation to prevent.

. OMRIX hemostatic sealant is currently approved in numerous countries, including the United States and the European Union.It is believed that the administration of the biological material into the temporary Epicardial fat modulation of the autonomic nervous system of the heart are obtained by blocking the vagal inputs to the heart as can be used as catalyst for the initiation of atrial fibrillation. There is no known pharmacological, immunological or metabolic interactions that occur and probably the company pre-clinical studies have shown that the biological material is removed in less than 30 days after the introduction the heart..That hexagon months after the attack less than 20 percent, had survived, fully recovered, and the results were even worse for those with blunt trauma as a for those who by penetrating wounds.